ALX Oncology (NASDAQ:ALXO) Trading Up 6.8%

ALX Oncology Holdings Inc. (NASDAQ:ALXO)’s share price shot up 6.8% on Tuesday . The company traded as high as $17.03 and last traded at $16.85. 423,219 shares changed hands during trading, a decline of 7% from the average session volume of 453,228 shares. The stock had previously closed at $15.78.

Wall Street Analysts Forecast Growth

ALXO has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of ALX Oncology in a report on Wednesday, April 10th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $14.00 price objective (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, ALX Oncology presently has an average rating of “Moderate Buy” and an average target price of $18.83.

ALX Oncology Stock Up 11.3 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The business has a 50 day moving average of $13.67 and a 200 day moving average of $12.65. The firm has a market capitalization of $878.00 million, a price-to-earnings ratio of -4.50 and a beta of 1.30.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). On average, equities analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

Insider Transactions at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the transaction, the insider now directly owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the insider now owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jason Lettmann acquired 4,400 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was acquired at an average price of $11.31 per share, with a total value of $49,764.00. Following the transaction, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. 50.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ALX Oncology

A number of large investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in ALX Oncology in the 4th quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of ALX Oncology by 66.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock valued at $107,000 after acquiring an additional 3,825 shares during the period. Barclays PLC boosted its holdings in ALX Oncology by 57.1% in the third quarter. Barclays PLC now owns 26,964 shares of the company’s stock valued at $129,000 after acquiring an additional 9,796 shares during the last quarter. SG Americas Securities LLC acquired a new stake in ALX Oncology in the third quarter worth about $48,000. Finally, Forefront Analytics LLC bought a new stake in ALX Oncology during the 3rd quarter worth about $66,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.